1. Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India.
- Author
-
Chatterjee D, Radotra BD, Aggarwal D, Madan R, and Gupta SK
- Subjects
- Adolescent, Adult, Child, Enhancer of Zeste Homolog 2 Protein metabolism, Female, Glioblastoma mortality, Glioblastoma radiotherapy, Humans, Immunohistochemistry methods, India epidemiology, Male, Microvascular Density, Middle Aged, Mutation, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local pathology, Radiotherapy methods, SMARCB1 Protein metabolism, Survival Analysis, Tertiary Care Centers, Young Adult, Brain Neoplasms pathology, Epithelioid Cells pathology, Glioblastoma diagnosis, Glioblastoma metabolism, Lymphocytes, Tumor-Infiltrating pathology, Proto-Oncogene Proteins B-raf metabolism
- Abstract
Background: Epithelioid glioblastoma (eGB) is a recently recognized and a rare variant of glioblastoma. This study aimed to describe the clinical, histological and immunohistochemical spectrum and outcome of eGB from a tertiary care hospital in north India., Materials and Methods: Twenty four cases of eGB diagnosed over past 10 years were reviewed with detailed morphological and immunohistochemical analysis (GFAP, EMA, Vimentin, Myogenin, INI-1, Cytokeratin, Synaptophysin, CD99, S100, MelanA, IDH1, ATRX, p16, EZH2, Ki-67, and BRAF V600E mutant antibody)., Result: The mean age was 29.9 years (3-54 years), with equal male and female patients. All had supratentorial tumor. All cases showed epithelioid cells in sheets; however, focal spindling (7 cases, 29.2%), grouping/nesting (6 cases, 25%) and papillary configuration (5 cases, 20.8%) were also noted. All showed microvascular proliferation (MVP) and all except one demonstrated areas of necrosis. INI1 was retained in all cases, while 2 showed patchy loss. EZH2 overexpression (>25%) was observed in 4 cases, while 5 cases showed loss of p16 expression. BRAF V600E mutant protein expression was seen in 12/23 (52.2%) cases. Outcome was available in 8 cases, out of which 6 (75%) experienced recurrence. The median survival was 25.5 months. Cases with tumor infiltrating lymphocytes had a better outcome., Conclusion: eGB is a distinct variant of glioblastoma which has predilection towards younger age group. It shows high percentage of BRAF V600E mutation and a subset of it shows longer survival. Cases with presence of tumor infiltrating lymphocytes are associated with better outcome., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF